Safety and Efficacy of Ravidasvir Plus Sofosbuvir in Hepatitis C

The Drugs for Neglected Diseases initiative (DNDi) presented a poster ‘Efficacy & safety of ravidasvir + sofosbuvir in hepatitis C: STORM-C-1 final results’ at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022.

Affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection in low and middle-income countries. STORM-C-1 aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in adults chronically infected with HCV, with or without HIV coinfection.

The study found that ravidasvir with sofosbuvir is well tolerated with excellent safety and efficacy in HCV infection, including difficult to treat populations, making it suitable for implementation in public health settings.

The poster can be downloaded here.